Why the study?
Does the combination of verapamil and a beta-blocker improve symptoms and remain tolerable in patients with angina resistant to monotherapy?
Does the combination of verapamil and a beta-blocker improve symptoms and remain tolerable in patients with angina resistant to monotherapy?
Combining verapamil and beta-blockers effectively reduces angina attacks in refractory patients but carries significant risks of bradyarrhythmias and left ventricular failure, necessitating close hospital-based monitoring.
May reduce angina frequency in refractory cases but risks LV failure and bradyarrhythmias; leaves open combination safety pending trials.
We have used a combination of a beta-blocker and verapamil to treat 42 consecutive patients with angina resistant to either agent alone. Patients with heart failure, heart block or uncontrolled hypertension were excluded. The mean duration of follow-up was 6.5 months. Thirty-six patients (81%) reported an improvement and the number of angina attacks was reduced from 17/week to 5/week. Side effects necessitated withdrawal of one or both drugs in 6 patients, 2 of whom developed bradyarrhythmias not solely related to drug treatment. The most common complication was mild left ventricular failure (6) treated by reducing or stopping the beta-blocker. The data suggest that the combination of verapamil and a beta-blocker may be used in a relatively unselected group of patients with difficult angina. However, as dosage adjustment and close observation may be necessary to minimise side effects, the use of this combination should be limited to hospital practice.
No takes yet. Share an insight, caveat, or question.
McGourty et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: